Noninvasive Serum Fibrosis Markers are Associated with Coronary Artery Calcification in Patients with Nonalcoholic Fatty Liver Disease|RISS 상세보기

다국어 초록 (Multilingual Abstract)

Background/Aims: Advanced hepatic fibrosis is associated with cardiovascular disease (CVD) in patients with nonalcoholic fatty liver disease (NAFLD). We investigated the association between noninvasive serum fibrosis markers and the coronary artery calcium score (CACS) in subjects with NAFLD.
Methods: We analyzed 665 NAFLD subjects without chronic liver disease or heart disease between 2011 and 2015.
The noninvasive fibrosis markers that were used to evaluate the severity of hepatic fibrosis included the NAFLD fibrosis score (NFS), fibrosis-4 (FIB-4) score, Forn’s index, and the aspartate aminotransferase to platelet ratio index (APRI). Results: The areas under the receiver operating characteristics curves for the NFS, FIB-4 score, Forn’s index and APRI for predicting CACS >100 were 0.689, 0.683, 0.659, and 0.595, respectively. According to the multivariate analysis, older age, increased body mass index (BMI), and decreased estimated glomerular filtration rate (eGFR) were significant factors associated with CACS >100. The NFS, FIB-4 score and APRI were significantly associated with CACS >100 after adjusting for age and gender (p=0.006, p=0.012, and p=0.012, respectively) and after adjusting for age, gender, BMI and eGFR (p=0.013, p=0.022, and p=0.027, respectively). Scores integrating noninvasive fibrosis markers and other risk factors improved the predictive accuracy. Conclusions: The NFS and FIB-4 score were associated with coronary atherosclerosis in subjects with NAFLD. Furthermore, scores integrating these noninvasive scores and risk factors for CVD showed good discriminatory power in predicting CACS >100. Therefore, noninvasive serum fibrosis markers may be useful tools for identifying NAFLD subjects at a high risk for CVD.

번역하기

참고문헌 (Reference)

1 Zhu Q, "Therapeutic effect of renin angiotensin system inhibitors on liver fibrosis" 17 : 1470320316628717-, 2016

2 Saadeh S, "The utility of radiological imaging in nonalcoholic fatty liver disease" 123 : 745-750, 2002

3 Adams LA, "The natural history of nonalcoholic fatty liver disease : a population-based cohort study" 129 : 113-121, 2005

4 Ampuero J, "The effects of metabolic status on non-alcoholic fatty liver disease-related outcomes, beyond the presence of obesity" 48 : 1260-1270, 2018

5 Chalasani N, "The diagnosis and management of non-alcoholic fatty liver disease : practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology" 142 : 1592-1609, 2012

6 Angulo P, "The NAFLD fibrosis score : a noninvasive system that identifies liver fibrosis in patients with NAFLD" 45 : 846-854, 2007

7 Bedogni G, "The Fatty Liver Index : a simple and accurate predictor of hepatic steatosis in the general population" 6 : 33-, 2006

8 Hwang IC, "Systemic Inflammation Is Associated With Coronary Artery Calcification and All-Cause Mortality in Chronic Kidney Disease" 80 : 1644-1652, 2016

9 Kwok R, "Systematic review with metaanalysis:non-invasive assessment of non-alcoholic fatty liver disease. The role of transient elastography and plasma cytokeratin-18fragments" 39 : 254-269, 2014

10 Tonelli M, "Risk of coronary events in people with chronic kidney disease compared with those with diabetes : a population-level cohort study" 380 : 807-814, 2012